Predicting Progress in Protein Aggregation
January 27, 2014 - by: Cynthia Challener, PhD. Biopharm International Techniques to enable the design and formulation of stable, protein-based therapeutics.


In silico analysis and t

Determining Criticality, Part Two: DoE and Data-Driven Criticalit


January 27, 2014 - by: Mark Mitchell, Biopharm International

A practical roadmap in three parts that applies scientific knowledge, risk analysis, experimental data, and process monitoring throughout the three phases of the pro

Regulation of Biosimilars: A Matter of Variability, Similarity, a


January 19, 2014 - By: Sean Milmo BioPharm International As the European Union takes a closer look at its biosimilars guidelines, some key issues are proving difficult to resolve.

Best Practices in Adopting Single-Use Systems
January 19, 2014 - By: John Schmitz BioPharm International

Key considerations for implementing single-use components or platforms when moving from research to process development.

Drugs, At What Cost?
January 19, 2014 - By: Rita Peters BioPharm International Generics, market dynamics, and global demand are changing drug spending patterns.


The underlying question for any

2014 Manufacturing Trends and Outlook
January 19, 2014 - By: Rita Peters BioPharm International Single-use systems and other technologies drive process efficiencies, but there is room for improvement.


Determining Criticality-Process Parameters and Quality Attributes


January 11, 2014 - By: Mark Mitchell BioPharm International A practical roadmap in three parts that applies scientific knowledge, risk analysis, experimental data, and process monitoring throughout the three phase

Implementing QbD in Sterile Manufacturing
December 31, 2013 - By: Susan Haigney, BioPharm International To gain perspective on the implementation of quality by design (QbD) in sterile manufacturing, BioPharm International spoke with Wolfgang Weikmann, vice-

Biotechnology Innovation and Growth in Israel
December 31, 2013 - By: Jill E. Sackman, Michael Kuchenreuther BioPharm International Israel's diverse population, high-quality healthcare system, and resilience to global financial stress make it a strong partner for R&D, clinical research, and

Climate Change in Outsourcing
December 31, 2013 - By: Jim Miller BioPharm International

As 2013 draws to a close, the bio/pharmaceutical industry continues to be reshaped by changes in the business climate. Financial, political, and scientific deve

Previous PageNext Page